Mirum Pharmaceuticals, Inc. today provided its preliminary and unaudited estimates for full-year 2024 net product sales, year-end cash balance, corporate updates, and full-year 2025 outlook. "2024 ...

Mirum stock rallies this week on upbeat preliminary 2024 results, the 2025 outlook and anticipated pipeline goals.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting ...

In unusual circumstances, Ipsen has been given the green light for its odevixibat drug for severe itching (pruritus) in patients with rare liver disease Alagille syndrome (ALGS) in the EU – for ...

Avanza Fonder AB acquired a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The ...

MIRM's flagship drug is Livmarli which was approved by the FDA in September 2021 to treat cholestatic pruritus in patients with Alagille syndrome ("ALGS"), a genetically driven multisystem disorder.

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) have been given a consensus rating of “Buy” by the eleven analysts that are presently covering the firm, Marketbeat.com reports.

These results suggest a mechanism that explains many of the cardiac defects seen in patients with Alagille syndrome, especially pulmonary artery stenosis. Jag1 haploinsufficiency during fetal life ...

Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). Ipsen is currently not running studies of odevixibat in PBC, but has a phase 3 programme on the go in biliary ...